Использование иммунобиологических препаратов в терапии ревматоидного артрит
https://doi.org/10.29235/1814-6023-2018-15-4-493-502
Аннотация
В данной статье рассматриваются вопросы оптимизации терапии ревматоидного артрита биологическими базисными противовоспалительными препаратами на основании определенных клинико-иммунологических предикторов. Приводится описание наиболее значимых предикторов, таких как индекс массы тела, курение, активность болезни, сопутствующая терапия и прогнозирование эффективности того или иного биологического препарата при наличии антител. Также приводятся данные о возможности прогнозирования ответа на определенный вид биологической терапии исходя из клинического варианта ревматоидного артрита.
Об авторах
М. В. Волкова
Белорусская медицинская академия последипломного образования, Минск
Беларусь
канд. мед. наук, вед. науч. сотрудник
Беларусь
канд. мед. наук, вед. науч. сотрудник
Е. В. Кундер
Белорусская медицинская академия последипломного образования, Минск
Беларусь
д-р мед. наук, профессор
Беларусь
д-р мед. наук, профессор
Список литературы
1. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force [Guideline] / J. S. Smolen [et al.] // Ann. Rheum. Dis. – 2016. – Vol. 75, N 1. – P. 3–15. https://doi.org/10.1136/annrheumdis-2015-207524
2. Kiely, P. D. W. Biologic efficacy optimization – a step towards personalized medicine/ P. D. W. Kiely // Rheumatology. – 2015. – Vol. 55, N 5. – P. 780–788. https://doi.org/10.1093/rheumatology/kev356
3. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review / J. T. Joensuu [et al.] // PLoS ONE. – 2015. – Vol. 10, N 3. – P. e0119683. https://doi.org/10.1371/journal.pone.0119683
4. Firestein, G. S. The disease formerly known as rheumatoid arthritis / G. S. Firestein // Arthritis Res. Ther. – 2014. – Vol. 16, N 3. – Art. 114. https://doi.org/10.1186/ar4593
5. Клинический полиморфизм ревматоидного артрита в белорусской популяции пациентов / Е. В. Кундер [и др.] // Медицина. – 2017. – № 2. – С. 63–70.
6. Current and future trends in biomarker discovery and development of companion diagnostics for arthritis / D. S. Gibson [et al.] // Expert Rev. Mol. Diagn. – 2014. – Vol. 15, N 2. – P. 219–234. https://doi.org/10.1586/14737159.2015.969244
7. Plant, D. Genetic and epigenetic predictors of responsiveness to treatment in RA / D. Plant, A. G. Wilson, A. Barton // Nat. Rev. Rheumatol. – 2014. – Vol. 10, N 6. – P. 329–337. https://doi.org/10.1038/nrrheum.2014.16
8. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics / G. Dennis Jr. [et al.] // Arthritis Res. Ther. – 2014. – Vol. 16, N 2. – P. R90. https://doi.org/10.1186/ar4555
9. Townsend, M. J. Molecular and cellular heterogeneity in the rheumatoid arthritis synovium: clinical correlates of synovitis / M. J. Townsend // Best Pract. Res. Clin. Rheumatol. – 2014. – Vol. 28, N 4. – P. 539–549. https://doi.org/10.1016/j.berh.2014.10.024
10. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register / K. L. Hyrich [et al.] // Rheumatology. – 2006. – Vol. 45, N 12. – P. 1558–1565. https://doi.org/10.1093/rheumatology/kel149
11. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA / J. L. Nam [et al.] // Ann. Rheumatic Dis. – 2010. – Vol. 69, N 6. – P. 976–986. https://doi.org/10.1136/ard.2009.126573
12. Daïen, C. I. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine / C. I. Daïen, J. Morel // Mediators Inflamm. – 2014. – Vol. 2014. – Art. ID 386148. https://doi.org/10.1155/2014/386148
13. Body mass index is an independent risk factor for not achieving sustained remission in early rheumatoid arthritis: results from the CATCH observational study / S. M. Goodman [et al.] // Ann. Rheum. Dis. – 2015. – Vol. 74, suppl. 2. – P. 138.2–139. https://doi.org/10.1136/annrheumdis-2015-eular.1973
14. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine / E. Gremese [et al.] // Arthritis Care Res. – 2012. – Vol. 65, N 1. – P. 94–100. https://doi.org/ 10.1002/acr.21768
15. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts / S. Saevarsdottir [et al.] // Arthritis Rheum. – 2010. – Vol. 63, N 1. – P. 26–36. https://doi.org/10.1002/art.27758
16. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register / L. E. Kristensen [et al.] // Rheumatology. – 2007. – Vol. 47, N 4. – P. 495–499. https://doi.org/10.1093/rheumatology/ken002
17. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British society for rheumatology biologics register / M. M. Soliman [et al.] // J. Rheumatol. – 2011. – Vol. 39, N 2. – P. 240–246. https://doi.org/10.3899/jrheum.110610
18. Van Schouwenburg, P. A. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis / P. A. van Schouwenburg, T. Rispens, G. J. Wolbink // Nat. Rev. Rheumatol. – 2013. – Vol. 9, N 3. – P. 164–172. https://doi.org/10.1038/nrrheum.2013.4
19. Кундер, Е. В. Иммуногенность блокаторов фактора некроза опухоли альфа как причина резистентности к терапии / Е. В. Кундер // Лечеб. дело. – 2017. – № 2. – С. 55–64.
20. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis / J. D. Isaacs [et al.] // Ann. Rheum. Dis. – 2012. – Vol. 72, N 3. – P. 329–336. https://doi.org/10.1136/ annrheumdis-2011-201117
21. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment / P. Lal [et al.] // Arthritis. Rheum. – 2011. – Vol. 63, N 12. – P. 3681–3691. https://doi.org/ 10.1002/art.30596
22. Personalized medicine for rheumatoid arthritis:serological and clinical patients profiles to optimize B and T cell targeted therapy / E. Feist [et al.] // Z. Rheumatol. – 2013. – Vol. 72, N 1. – P. 49–58. https://doi.org/ 10.1007/s00393-011-0885-4
23. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis / J. Sellam [et al.] // Arthritis Res. Ther. – 2016. – Vol. 18, N 1. – Р. 294. https://doi.org/ 10.1186 / s13075-016-1190-z
24. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-tnfa agent treatment in patients with rheumatoid arthritis: a meta-analysis / Q. Lv [et al.] // Plos ONE. – 2014. – Vol. 9, N 2. – P. e89442. https://doi.org/10.1371/journal.pone.0089442
25. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial / D. Porter [et al.] // Lancet. – 2016. – Vol. 388, N 10041. – P. 239–247. https://doi.org/10.1016/s0140-6736(16)00380-9
26. Singh, J. A. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review / J. A. Singh, S. Beg, M. A. Lopez-Olivo // J. Rheumatol. – 2011. – Vol. 38, N 1. – P. 10–20. https://doi.org/10.3899/jrheum.100717
27. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis / R. Alfonso-Cristancho [et al.] // Clin. Rheumatol. – 2016. – Vol. 36, N 1. – P. 25–34. https://doi.org/10.1007/ s10067-016-3435-2
28. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial / C. Gabay [et al.] // Lancet. – 2013. – Vol. 381, N 9877. – P. 1541–1550. https://doi.org/10.1016/s0140-6736(13)60250-0
29. Alam, J. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy / J. Alam, I. Jantan, S. N. A. Bukhari // Biomed. Pharmacother. – 2017. – Vol. 92. – P. 615–633. https://doi.org/10.1016/j.biopha.2017.05.055
30. Nishimoto, N. Interleukin 6: from bench to bedside / N. Nishimoto, T. Kishimoto // Nat. Clin. Pract. Rheumatol. – 2006. – Vol. 2, N 11. – P. 619–626. https://doi.org/10.1038/ncprheum0338
31. Effectiveness of biologic and non biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: new evidence from real-world data / S. K. Paul [et al.] // Semin. Arthr. Rheum. – 2018. – Vol. 47, N 4. – P. 478–484. https://doi.org/10.1016/j.semarthrit.2017.08.001
32. Pandian, V. P. Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies / V. P. Pandian, R. Srinivasan // Clin. Ophthalmol. – 2015. – Vol. 9. – P. 393–397. https://doi.org/10.2147/opth.s77210
33. Assmann, G. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers / G. Assmann, M. Pfreundschuh, J. Voswinkel // Clin. Exp. Rheumatol. – 2010. – Vol. 28, N 1, suppl. 57. – P. 81–83.
34. Chandra, P. A. Rituximab is useful in the treatment of Felty’s syndrome / P. A. Chandra, Y. Margulis, C. Schiff // Am. J. Ther. – 2008. – Vol. 15, N 4. – P. 321–322. https://doi.org/10.1097/mjt.0b013e318164bf32
35. Iaccheri, B. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis / B. Iaccheri [et al.] // Ocul. Immunol. Infamm. – 2010. – Vol. 18, N 3. – P. 223–225. https://doi.org/10.3109/09273941003739928
36. Coexistence of rheumatoid arthritis and ankylosing spondylitis / T. A. Barczyńska [et al.] // Reumatologia. – 2015. – Vol. 5. – P. 279–285. https://doi.org/10.5114/reum.2015.55832
37. Double disease in rheumatology: coexistence of rheumatoid arthritis and psoriatic arthritis / R. Mazzucchelli [et al.] // Clin. Exp. Rheumatol. – 1992. – Vol. 10 (1). – P. 83–85.
38. Toussirot, E. Crohn’s disease associated with seropositive rheumatoid arthritis / E. Toussirot, D. Wendling // Clin. Exp. Rheumatol. – 1997. – Vol. 15, N 3. – P. 307–311.
39. Bogas, M. Erosive enteropathy in a patient with polyarthritis / M. Bogas, M. C. Afonso, D. Araújo // Acta Reumatol. Port. – 2006. – Vol. 31, N 4. – P. 349–354.
40. Ulcerative colitis and rheumatoid arthritis: a rare association--case report / V. A. Cruz [et al.] // Rev. Bras. Reumatol. – 2012. – Vol. 52, N 4. – P. 648–650.
41. Azevedo, V. F. Concurrent rheumatoid arthritis and ankylosing spondylitis in one patient: the importance of new classification criteria / V. F. Azevedo, P. G. Buiar // Rev. Bras. Reumatol. (En. ed.). – 2013. – Vol. 53, N 1. – P. 111–119. https://doi.org/10.1016/s2255-5021(13)70011-7
42. Association of HLA alleles and clinical features in patients with synovitis of recent onset / H. S. El-Gabalawy [et al.] // Arthritis Rheum. – 1999. – Vol. 42, N 8. – P. 1696–1705. https://doi.org/10.1002/1529-0131(199908)42:83.0.co;2-k
43. Jajić, Z. HLA B27 antigen and rheumatoid arthritis / Z. Jajić, I. Jajić // Acta Med. Iugosl. – 1991. – Vol. 45, N 3. – P. 195–202.
44. Ultrasonographic assessment of enthesitis in HLA-B27 positive patients with rheumatoid arthritis, a matched case-only study / A. Mera-Varela [et al.] // PLoS ONE. – 2013. – Vol. 8, N 3. – P. e58616. https://doi.org/10.1371/journal.pone.0058616
45. HLA-B27 in French patients with rheumatoid arthritis / A. Saraux [et al.] // Scand. J. Rheumatol. – 1997. – Vol. 26, N 4. – P. 269–271. https://doi.org/10.3109/03009749709105315
46. Jurik, A. G. Radiographic visualisation of seropositive rheumatoid arthritis in carriers of HLA-B27 / A. G. Jurik, A. de Carvalho, H. Graudal // RöFo – Fortschritte auf dem Gebiet der R. – 1987. – Vol. 147, N 7. – P. 14–20. https://doi.org/10.1055/s-2008-1048582
Рецензия
Для цитирования:
Волкова М.В., Кундер Е.В. Использование иммунобиологических препаратов в терапии ревматоидного артрит. Известия Национальной академии наук Беларуси. Серия медицинских наук. 2018;15(4):493-502. https://doi.org/10.29235/1814-6023-2018-15-4-493-502
For citation:
Volkava M.V., Kunder A.V. Use of immunobiological drugs in the treatment of rheumatoid arthritis. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2018;15(4):493-502. (In Russ.) https://doi.org/10.29235/1814-6023-2018-15-4-493-502
Просмотров: 833
Послать статью по эл. почте 